



Sample Information

Patient Name: 賴明得**Gender:** Male**ID No.:** F102628100**History No.:** 17188691**Age:** 73**Ordering Doctor:** DOC3153J 黃煦晴**Ordering REQ.:** C2G9P1A**Signing in Date:** 2022/11/03**Path No.:** S111-97969**MP No.:** F22117**Assay:** Oncomine Focus Assay**Sample Type:** FFPE**Block No.:** S111-42472A**Percentage of tumor cells:** 20%**Reporting Doctor:** DOC5466K 葉奕成 (Phone: 8#5466)**Note:**

Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents	Page
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2
Biomarker Descriptions	2
Relevant Therapy Summary	3
Relevant Therapy Details	4
Clinical Trials Summary	6
Alert Details	6

Report Highlights

1 Relevant Biomarkers
1 Therapies Available
6 Clinical Trials

Relevant Non-Small Cell Lung Cancer Variants

Gene	Finding	Gene	Finding
ALK	None detected	NTRK1	None detected
BRAF	None detected	NTRK2	None detected
EGFR	None detected	NTRK3	None detected
ERBB2	ERBB2 exon 20 insertion	RET	None detected
KRAS	None detected	ROS1	None detected
MET	None detected		

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	ERBB2 exon 20 insertion erb-b2 receptor tyrosine kinase 2 Allele Frequency: 12.54%	trastuzumab deruxtecan ¹	None	6

Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
ERBB2	p.(Y772_A775dup)	c.2324_2325insATAC GTGATGGC	COSM20959	chr17:37880981	12.54%	NM_004448.3	nonframeshift Insertion	1985

Biomarker Descriptions

ERBB2 (erb-b2 receptor tyrosine kinase 2)

Background: The ERBB2 gene encodes the erb-b2 receptor tyrosine kinase 2, a member of the human epidermal growth factor receptor (HER) family. Along with ERBB2/HER2, EGFR/ERBB1/HER1, ERBB3/HER3, and ERBB4/HER4 make up the HER protein family¹. All ERBB/HER proteins encode transmembrane receptor tyrosine kinases. However, ERBB2/HER2 is an orphan receptor with no known ligand. ERBB2 preferentially binds other ligand bound ERBB/HER family members to form hetero-dimers resulting in the activation of ERBB2 tyrosine kinase activity and subsequent activation of the PI3K/AKT/MTOR and RAS/RAF/MAPK/ERK signaling pathways which promote cell proliferation, differentiation, and survival². Recurrent focal amplification of the ERBB2 gene leads to increased expression in several cancer types. ERBB2 overexpression in immortalized cell lines is oncogenic and leads to ERBB2 homo-dimerization and activation without ligand binding^{3,4,5}.

Alterations and prevalence: ERBB2 gene amplification occurs in 10-20% of breast, esophageal, and gastric cancers, 5-10% of bladder, cervical, pancreas, and uterine cancers, and 1-5% of colorectal, lung, and ovarian cancers^{6,7,8,9,10,11,12,13}. Recurrent somatic activating mutations in ERBB2/HER2 occur at low frequencies (<1%) in diverse cancer types^{13,14,15}. In breast, bladder, and colorectal cancers, the most common recurrent ERBB2 activating mutations include kinase domain mutations L755S and V777L and the extracellular domain mutation S310F. In lung cancer, the most common recurrent ERBB2 activating mutations include in-frame exon 20 insertions, particularly Y772_A775dup.

Potential relevance: The discovery of ERBB2/HER2 as an important driver of breast cancer in 1987 led to the development of trastuzumab, a humanized monoclonal antibody with specificity to the extracellular domain of HER2^{16,17}. Trastuzumab¹⁸ was FDA approved for the treatment of HER2 positive breast cancer in 1998, and subsequently in HER2 positive metastatic gastric and gastroesophageal junction adenocarcinoma in 2010. Additional monoclonal antibody therapies have been approved by the FDA for HER2-positive breast cancer including pertuzumab¹⁹ (2012), a humanized monoclonal antibody that inhibits HER2 dimerization, and ado-trastuzumab emtansine²⁰ (2013), a conjugate of trastuzumab and a potent antimicrotubule agent. The combination of pertuzumab, trastuzumab, and a taxane is the preferred front-line regimen for HER2-positive metastatic breast cancer²¹. In addition to monoclonal antibodies, the small molecule inhibitor lapatinib²², with specificity for both EGFR and ERBB2, was FDA approved (2007) for the treatment of patients with advanced HER2-positive breast cancer who have received prior therapy including trastuzumab. In 2017, the FDA approved the use of neratinib²³, an irreversible kinase inhibitor of EGFR, ERBB2/HER2, and ERBB4, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer. In 2020, the FDA approved neratinib²³ in combination with capecitabine for HER2-positive advanced or metastatic patients after two or more prior HER2-directed therapies. Also in 2020, the TKI irinitinib²⁴ was FDA approved for HER2 overexpressing or amplified breast cancer in combination with trastuzumab and capecitabine. In 2021, the PD-1 blocking antibody, pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-based chemotherapy, was approved for HER2 amplified gastric or gastroesophageal (GEJ) adenocarcinoma in the first line²⁵. The vaccine, nelipepimut-S²⁶, was granted fast-track designation by the FDA (2016) in patients with low to intermediate HER2 expressing (IHC score 1+ or 2+) breast cancer. In 2018 fast-track designation was granted to the monoclonal antibody margetuximab²⁷ in patients with ERBB2 positive breast cancer previously treated with an anti-HER2 therapy. In 2019, fast track designation was granted to the HER2-targeting antibody drug conjugate, amcenestrant²⁸, for HER2-positive advanced or metastatic breast cancer after one or more

Biomarker Descriptions (continued)

prior anti-HER2 based regimens. Additionally, in 2019, the novel bispecific antibody, zanidatamab²⁹, received fast-track designation in combination with standard chemotherapy for patients with HER2-overexpressing gastroesophageal adenocarcinoma (GEA) and breakthrough therapy designation (2020) as a monotherapy for patients with HER2-amplified biliary tract cancer³⁰. In 2020, BDTX-189³¹ received fast-track designation for adult patients with solid tumors harboring an allosteric human ERBB2 mutation or exon 20 insertion, and the humanized anti-HER2 antibody drug conjugate disitamab vedotin received breakthrough designation for adult patients with HER2-positive urothelial cancer after previous platinum-chemotherapy treatment³². In 2021, the antibody-drug conjugate ARX788³³ received fast-track designation as a monotherapy for advanced or metastatic HER2-positive breast cancer that have progressed on one or more anti-HER2 regimens. Additionally, in 2021, fast track designation was granted to HER2 targeted chimeric antigen receptor macrophage (CAR-M), CT-0508³⁴, for HER2-overexpressing solid tumors. Certain activating mutations have been observed to impart sensitivity to neratinib, afatinib, lapatinib, and trastuzumab, or dacomitinib in early and ongoing clinical studies^{35,36,37,38,39}. ERBB2 kinase domain mutations R896G and V659E both showed response to afatinib in two NSCLC case studies^{40,41}. Additionally, acquired HER2 mutations in estrogen receptor-positive (ER+) breast cancer have been shown to confer resistance to hormone therapy⁴². However, this was shown to be overcome by neratinib in combination with therapies targeting ER⁴².

Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

ERBB2 exon 20 insertion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
trastuzumab deruxtecan	●	●	×	×	×
pyrotinib	×	×	×	×	● (III)
trastuzumab deruxtecan, pembrolizumab, chemotherapy	×	×	×	×	● (III)
ado-trastuzumab emtansine	×	×	×	×	● (II)
sunvozertinib	×	×	×	×	● (I/II)
SAR-443216	×	×	×	×	● (I)
SHR-A1811	×	×	×	×	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

☒ In this cancer type ☐ In other cancer type ☒ In this cancer type and other cancer types

FDA information is current as of 2022-08-17. For the most up-to-date information, search www.fda.gov.

ERBB2 exon 20 insertion

☒ trastuzumab deruxtecan

Cancer type: Non-Small Cell Lung Cancer

Label as of: 2022-08-11

Variant class: ERBB2 exon 20 insertion or ERBB2 activating mutation

Indications and usage:

ENHERTU® is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:

- adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:
 - in the metastatic setting, or
 - in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
- adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
- adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
 - This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf

Current NCCN Information

- ☒ In this cancer type ☐ In other cancer type ☐ In this cancer type and other cancer types

NCCN information is current as of 2022-08-01. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

ERBB2 exon 20 insertion

● trastuzumab deruxtecan

Cancer type: Non-Small Cell Lung Cancer

Variant class: ERBB2 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 3.2022]

Clinical Trials in Taiwan region:

Clinical Trials Summary

ERBB2 exon 20 insertion

NCT ID	Title	Phase
NCT03974022	A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation	I/II
NCT04447118	A Phase III, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy	III
NCT05048797	An Open-label, Randomized, Multicenter, Phase III Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)	III
NCT05013554	A Phase I/Ib Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants with Relapsed/Refractory HER2 Expressing Solid Tumors.	I
NCT04589845	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	II
NCT04446260	A Phase I Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects	I

Alerts Informed By Public Data Sources

Current FDA Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

FDA information is current as of 2022-08-17. For the most up-to-date information, search www.fda.gov.

ERBB2 exon 20 insertion

BDTX-189

Cancer type: Solid Tumor

Variant class: ERBB2 exon 20 insertion

Supporting Statement:

The FDA has granted Fast Track Designation to BDTX-189 for solid tumors harboring a HER2 mutation or an EGFR or HER2 exon 20 insertion after progression on prior therapy.

Reference:

<https://investors.blackdiamondtherapeutics.com/news-releases/news-release-details/black-diamond-therapeutics-granted-fast-track-designation-fda>

Current NCCN Information

 Contraindicated  Not recommended  Resistance  Breakthrough  Fast Track

NCCN information is current as of 2022-08-01. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

ERBB2 exon 20 insertion

afatinib

Cancer type: Non-Small Cell Lung Cancer **Variant class:** ERBB2 mutation

Summary:

NCCN Guidelines® include the following supporting statement(s):

- "The NCCN NSCLC Panel does not recommend single-agent therapy with trastuzumab or afatinib for patients with ERBB2 mutations, because response rates are lower and treatment is less effective with these agents."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 3.2022]

trastuzumab

Cancer type: Non-Small Cell Lung Cancer **Variant class:** ERBB2 mutation

Summary:

NCCN Guidelines® include the following supporting statement(s):

- "The NCCN NSCLC Panel does not recommend single-agent therapy with trastuzumab or afatinib for patients with ERBB2 mutations, because response rates are lower and treatment is less effective with these agents."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 3.2022]

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

References

1. King et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. *Science*. 1985 Sep 6;229(4717):974-6. PMID: 2992089
2. Gutierrez et al. HER2: biology, detection, and clinical implications. *Arch. Pathol. Lab. Med.* 2011 Jan;135(1):55-62. PMID: 21204711
3. Di et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. *Science*. 1987 Jul 10;237(4811):178-82. PMID: 2885917
4. Hudziak et al. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. *Proc. Natl. Acad. Sci. U.S.A.* 1987 Oct;84(20):7159-63. PMID: 2890160
5. Lonardo et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. *New Biol.* 1990 Nov;2(11):992-1003. PMID: 1983208
6. Ciriello et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*. 2015 Oct 8;163(2):506-19. PMID: 26451490
7. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23. PMID: 25079317
8. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29. PMID: 24476821
9. Donna et al. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012 Jul 18;487(7407):330-7. PMID: 22810696
10. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9. PMID: 25079552
11. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011 Jun 29;474(7353):609-15. PMID: 21720365
12. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
13. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
14. Petrelli et al. Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. *Breast Cancer Res. Treat.* 2017 Nov;166(2):339-349. PMID: 28762010
15. Bose et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. *Cancer Discov.* 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7. PMID: 23220880
16. Hudis. Trastuzumab—mechanism of action and use in clinical practice. *N. Engl. J. Med.* 2007 Jul 5;357(1):39-51. PMID: 17611206
17. Slamon et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987 Jan 9;235(4785):177-82. PMID: 3798106
18. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf
19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf
20. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf
21. NCCN Guidelines® - NCCN-Breast Cancer [Version 4.2022]
22. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf
23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf
24. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf
25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf
26. <https://www.globenewswire.com/news-release/2016/06/01/845166/0/en/Galena-Biopharma-Receives-Fast-Track-Designation-for-NeuVax-nelipepimut-S-PRESENT-Clinical-Trial.html>
27. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf
28. <https://www.prnewswire.com/news-releases/fda-grants-arx788-fast-track-designation-for-her2-positive-metastatic-breast-cancer-301199951.html>
29. <https://www.targetedonc.com/view/her2targeted-antibody-zw25-earns-fda-fast-track-designation-in-gea>
30. <https://www.targetedonc.com/view/fda-grants-breakthrough-designation-to-zanidatamab-for-her2-amplified-biliary-tract-cancer>
31. <https://investors.blackdiamondtherapeutics.com/news-releases/news-release-details/black-diamond-therapeutics-granted-fast-track-designation-fda>

References (continued)

32. <https://www.prnewswire.com/news-releases/remegen-announces-us-fda-has-granted-breakthrough-therapy-designation-for-disitamab-vedotin-rc48-in-urothelial-cancer-301138315.html>
33. <http://ambrx.com/fda-grants-arx788-fast-track-designation-for-her2-positive-metastatic-breast-cancer>
34. <https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-us-food-and-drug-administration-grants-fast-track-designation-to-ct-0508-for-the-treatment-of-patients-with-solid-tumors-301381843.html>
35. Ma et al. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. *Clin. Cancer Res.* 2017 Oct 1;23(19):5687-5695. PMID: 28679771
36. De et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. *Lung Cancer.* 2012 Apr;76(1):123-7. PMID: 22325357
37. Kris et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. *Ann. Oncol.* 2015 Jul;26(7):1421-7. PMID: 25899785
38. Falchook et al. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. *J Thorac Oncol.* 2013 Feb;8(2):e19-20. PMID: 23328556
39. David et al. Neratinib in HER2- or HER3-mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 'basket' study. *AACR 2017. Abstract CT001*
40. Lin et al. Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report. *Onco Targets Ther.* 2019;12:10897-10902. PMID: 31849493
41. Chang et al. Sustained Partial Response to Afatinib in a Patient With Lung Adenocarcinoma Harboring HER2V659E Mutation. *JCO Precis Oncol.* 2020 Aug; 912-915. DOI: 10.1200/PO.20.00114
42. Nayar et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. *Nat. Genet.* 2019 Feb;51(2):207-216. PMID: 30531871